Coccidioidomycosis
📧 Sign up to get email alerts when something new happens for Coccidioidomycosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-01EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
EMA authorises Noxafil (posaconazole) for multiple fungal infections including candidiasis, mycoses, coccidioidomycosis, and aspergillosis.
-
EMA approval · 2026-06-12EMA Authorised: Posaconazole Accord (posaconazole) — Accord Healthcare S.L.U.
Authorised status for Posaconazole Accord, MAH Accord Healthcare S.L.U., in the therapeutic area of mycoses.
-
EMA approval · 2026-04-22EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
The EMA has granted marketing authorization for Noxafil (posaconazole) by Merck Sharp & Dohme B.V. for the treatment and prevention of funga…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
A National Institute of Allergy and Infectious Diseases–sponsored clinical trial is recruiting to study the pathogenesis and genetic factors…
-
FDA approval · 2025-06-02FDA Approved: AMPHOTERICIN B — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original application for Amphotericin B as a generic drug by Heritage Pharmaceuticals (Avet) to treat serious systemic funga…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment [Phase 1, Phase 2]
The trial evaluated Nikkomycin Z for treating coccidioidomycosis in a Phase 1/2 study. The study was terminated and safety and pharmacokinet…
-
FDA approval · 2025-03-12FDA Approved: ITRACONAZOLE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for itraconazole from Ascend Laboratories, LLC, authorizing changes to the generic product under AND…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment [Phase 3]
Phase 3 study assessing ibrexafungerp in patients with invasive and mucocutaneous fungal diseases refractory to or intolerant of standard tr…
-
FDA approval · 2024-10-24FDA Approved: ITRACONAZOLE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for itraconazole from Alembic Pharmaceuticals Inc., resulting in a label-related approval update for…
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.
A completed clinical trial conducted at three Costa Rican hospitals evaluating therapies for rare dermatological infections, including sporo…
-
FDA approval · 2023-07-17FDA Approved: FLUCONAZOLE IN SODIUM CHLORIDE — Supplemental Application (Hospira, Inc.)
FDA approved Hospira's supplemental application for Fluconazole in Sodium Chloride, establishing an intravenous formulation of fluconazole. …
-
FDA approval · 2023-03-17FDA Approved: FLUCONAZOLE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for fluconazole submitted by Rising Pharma Holdings, Inc., indicating approval of a generic formulat…
-
CLINICAL_TRIALS trial_result · 2023-01-11Clinical Trial Update: Safety and Pharmacokinetics of VT-1598 [Phase 1]
Phase 1 safety and pharmacokinetic data for the antifungal VT-1598 in coccidioidomycosis have been reported.
-
FDA approval · 2022-11-17FDA Approved: AMPHOTERICIN B — Original Application (Eugia US LLC)
FDA approved the original ANDA for Amphotericin B from Eugia US LLC, authorizing a generic Amphotericin B product.
-
FDA approval · 2019-07-16FDA Approved: FLUCONAZOLE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Fluconazole from Zydus Lifesciences Limited, resulting in regulatory approval of this generic pr…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) [Phase 4]
Phase 4 trial evaluating efficacy of fluconazole for coccidioidomycosis pneumonia (valley fever) was terminated; results posted in 2019.
-
FDA approval · 2016-09-26FDA Approved: ITRACONAZOLE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original application for itraconazole, granting a generic version of the antifungal medication. Th…
-
CLINICAL_TRIALS safety_alert · 2015-12-14Clinical Trial Update: Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
Clinical trial update examining the risk of coccidioidomycosis in patients with inflammatory arthritis treated with anti-TNF and other biolo…
-
CLINICAL_TRIALS trial_result · 2013-10-29Clinical Trial Update: A Multi-center Study of Spherule-Derived Coccidioidin [Phase 3]
A Phase 3 multicenter clinical trial evaluating Spherule-Derived Coccidioidin for Coccidioidomycosis has completed.
-
FDA approval · 2012-01-25FDA Approved: FLUCONAZOLE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for fluconazole submitted by Hikma Pharmaceuticals USA Inc.
-
FDA approval · 2011-08-25FDA Approved: KETOCONAZOLE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved Padagis Israel Pharmaceuticals Ltd's Ketoconazole original application (ANDA 091550) for a generic ketoconazole product.
-
CLINICAL_TRIALS trial_result · 2010-06-30Clinical Trial Update: POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) [Phase 3]
A Phase 3 trial comparing posaconazole versus fluconazole as first-line therapy for coccidioidomycosis has completed, with results posted in…
-
FDA approval · 2010-03-05FDA Approved: AMPHOTERICIN B — Supplemental Application (XGen Pharmaceuticals DJB, Inc.)
FDA approved a supplemental application for Amphotericin B submitted by XGen Pharmaceuticals DJB, Inc. This approval authorizes a change to …
-
EMA withdrawal · 2009-08-04EMA Lapsed: Posaconazole SP (posaconazole) — Schering-Plough Europe
EMA status shows Posaconazole SP has lapsed; therapeutic areas include candidiasis, mycoses, coccidioidomycosis, and aspergillosis.